Objective  To evaluate the efficacy and safety of osimertinib and bevacizumab combination therapy for brain metastases in 14 patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma.

  Methods  The clinical data of 14 patients with EGFR-mutant lung adenocarcinoma brain metastases treated at the Guangzhou Chest Hospital from January 2017 to December 2019 were retrospectively analyzed. They received a combination of osimertinib and bevacizumab treatment, repeated every 3 weeks, and were observed for drug efficacy and adverse reactions.

  Results  Among the 14 patients, 11 (78.6%) achieved partial response in their brain metastases, two (14.3%) had stable disease, and one (7.1%) had progressive disease. The objective response rate was 78.6% (11/14), the disease control rate was 92.9% (13/14), and the median progression-free survival (mPFS) was 12.5 months (95%CI: 8.53~15.87). The most common adverse events noted were anemia (57.1%), hypertension (50.5%), and proteinuria (28.6%).No patient discontinued treatment due to adverse reactions.

  Conclusions  The clinical efficacy of osimertinib and bevacizumab combination treatment for EGFR-mutant lung adenocarcinoma brain metastases looks promising, and it seems that adverse reactions can be controlled; however, clinical analysis of a larger series of samples is needed.